Berirab

Human Rabies Immunoglobulin (Berirab) is a post-exposure treatment for rabies. This product, manufactured by CSL Behring GmbH, is administered intramuscularly to provide immediate protection against the rabies virus.

Human Rabies Immunoglobulin is primarily used for post-exposure prophylaxis in individuals who have been bitten by animals suspected or confirmed to have rabies. It works by providing immediate passive immunity to the rabies virus, complementing the effects of the rabies vaccine. This treatment is crucial for preventing the onset of rabies symptoms after exposure.

Common effects of Human Rabies Immunoglobulin may include localized reactions at the injection site, such as pain, swelling, or redness. Some individuals might experience mild systemic reactions like fever or headache. These effects are generally temporary and subside on their own.

Human Rabies Immunoglobulin should be administered with caution in individuals with a history of allergic reactions to similar products. It is important to inform healthcare providers about any existing medical conditions or allergies before receiving this treatment. Proper storage and handling are essential to maintain its efficacy.

Human Rabies Immunoglobulin may interact with certain medications, particularly those that affect the immune system. It is advisable to consult with a healthcare provider about any ongoing treatments before receiving this product. Alcohol and other substances that suppress the immune system should be avoided to ensure the effectiveness of the treatment.